DOCSLIB.ORG

Long-Term Follow-Up of a Single Institution Pilot Study of Sirolimus

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Long-Term Follow-Up of a Single Institution Pilot Study of Sirolimus Annals of Hematology (2019) 98:237–240 https://doi.org/10.1007/s00277-018-3427-1 LETTER TO THE EDITOR Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation Tae Kon Kim1 & Michelle DeVeaux 2 & Maximilian Stahl1 & Sarah Perreault & Iris Isufi1 & Dennis Cooper3 & Francine Foss1 & Warren Shlomchik4 & Daniel Zelterman2 & Amer M. Zeidan1 & Stuart Seropian1 Received: 13 March 2018 /Accepted: 30 June 2018 /Published online: 19 July 2018 # Springer-Verlag GmbH Germany, part of Springer Nature 2018 Dear Editor, been traditionally performed using a calcineurin inhibitor in Allogeneic stem cell transplantation (allo-SCT) is a poten- combination with a short course of methotrexate [7, 8]. tially curative treatment for patients with hematologic malig- These regimens effectively prevent severe GVHD in the nancies [1]. However, overall survival (OS) is often compro- majority of MSD and MUD transplantation. However, there mised by treatment-related complications such as graft- is no uniformly accepted guideline for GVHD prophylaxis versus-host disease (GVHD). Recipients of fully HLA- for MMUD transplants. matched sibling donors (MSD) have an acute GVHD rates Sirolimus is an immunosuppressant derived from between 30 and 40% and severe life-threatening acute Streptomyces hygroscopicus [9], which is structurally similar GVHD may occur in 15% of patients [2, 3]. Many patients to tacrolimus [10]. Sirolimus binds mammalian target of who could potentially benefit from allo-SCT do not have a rapamycin (mTOR), that inhibits co-stimulatory pathway MSD or a matched unrelated donor (MUD) based on high- (e.g., CD28-AKT) and IL-2 driven pathway [11]. Sirolimus resolution molecular matching techniques [4]. Partially, HLA- has potent anti-rejection activity in solid organ transplantation mismatched unrelated donor (MMUD) transplantation is a [12] and demonstrated activity as therapy of steroid-resistant viable option for patients lacking a fully matched donor; how- GVHD [13]. Since tacrolimus and sirolimus have distinct ever, HLA mismatches significantly increase the risk of mechanisms of action, combination therapy confers a syner- GVHD and confer an inferior OS [5]. gistic effect [14, 15] to inhibit rejection in human organ allo- Treatment for acute GVHD is not successful in all pa- grafting. Sirolimus does not cause nephrotoxicity and neuro- tients and may impact long-term survival. Patients with toxicity, and is therefore less likely to cause synergistic ad- grade III–IV acute GVHD who do not respond to frontline verse effects with a calcineurin inhibitor. therapy with corticosteroids have only a 30% 2-year overall The combination of sirolimus, tacrolimus, and low-dose survival [6]. Pharmacologic immunosuppression is the most methotrexate was initially tested as GVHD prophylaxis in commonly applied method for prevention of GVHD and has both matched related and limited numbers of mismatched related transplants, with reported rates of overall acute GVHD of 26% and severe acute GVHD (grades III–IV) of * Stuart Seropian 13% [16]. Here, we aimed to study the activity of sirolimus/ [email protected] tacrolimus/low-dose methotrexate solely in MMUD trans- plantation and performed extended follow-up of patients 1 Section of Hematology/Department of Internal Medicine and Yale Cancer Center, Smilow Cancer Hospital at Yale-New Haven, Yale registered in our pilot study. University School of Medicine, New Haven, USA This pilot study enrolled 25 recipients of MMUD allografts 2 Department of Public Health, Yale University, New Haven, USA recruited at Yale University between 2008 and 2011. We mon- itored the efficacy of a regimen of sirolimus, tacrolimus, and 3 Rutgers Cancer Institute of New Jersey, New Brunswick, USA methotrexate as GVHD prophylaxis for MMUD allo-grafting 4 University of Pittsburgh School of Medicine, Division of with extended follow-up until 2015. This study was approved Hematology and Oncology, Department of Medicine, UPMC Hillman Cancer Center, Pittsburgh, USA by the Institutional Review Board of Yale University and 238 Ann Hematol (2019) 98:237–240 patients consented in written form. Patients were older than Table 1 Patient characteristics 16 years of age and received a MMUD allograft defined as 8/ N 25 10 or 9/10 HLA matching. Patients whose best available do- Median age, in years (range) 55 (20–72) nor matched at 8/10 loci were required to have at least one of Sex, n, M/F 15/10 the mismatches at the DQ locus. For patients with best donor Stem cell source, n (%) peripheral blood stem cells 25 (100) matched at 9/10 loci, single DQ mismatches were not permit- Donor mismatched unrelated 7/8 match, n (%) 25 (100%) ted. All patients received G-CSF mobilized peripheral blood Diagnosis stem cells (PBSCs). A minimum of 2 × 106 CD34+ cells/kg AML, n (%) 11 (44) were administered to recipients. Tacrolimus was administered ● In CR1 ● 1(4) initially by continuous infusion beginning day −3 until able to ● In CR2 ● 5(20) take oral medication reliably, targeting levels between 5 and ● In CR3 ● 1(4) 10 ng/ml. Tacrolimus was continued until day +120 post- ● Primary induction failure ● 1(4) transplant. Tacrolimus could be dose reduced or discontinued ● Relapsed ● 2(8) in the case of drug-related toxicity, or the development of APL (CR3), n (%) 1 (4) disease recurrence. Sirolimus was administered as a 12-mg oral loading dose on day −3 followed by 4 mg daily. CML-AP, n (%) 1 (4) Sirolimus levels were obtained on day 0 and then at least twice MDS 1 (4) weekly to maintain trough serum levels of 3–12 ng/ml. ALL, Ph-, n (%) ● Sirolimus was continued until day +150 and could be dose In CR1 2 (8) ● reduced in the case of toxicity, or the development of disease In CR2 1 (4) recurrence. For recipients of reduced intensity conditioning, ALL, Ph+, n (%) 1 (4) MTX was given on day +1 (10 mg/m2) and day +3 (5 mg/m2). MPN, n (%) 1 (4) For recipients of high-dose conditioning, a single dose of Hodgkin disease, relapsed 1 (4) methotrexate (5 mg/m2) was administered on day +1 only. Recurrent lymphoplasmacytic lymphoma 1 (4) Leucovorin (15 mg) was given every 6 h for 48 h after meth- Recurrent mantle cell lymphoma 1 (4) otrexate therapy. NHL, n (%), relapsed and refractory 2 (8) Baseline characteristics were summarized using descriptive Aplastic anemia, n (%), therapy related 1 (4) statistics. Relapse-free survival (RFS) and OS were calculated Conditioning regimen using the Kaplan-Meier estimate. Cumulative incidence of Myeloablative, n (%) 7 (28) non-relapsed mortality (NRM) and relapse were evaluated Reduced intensity, n (%) 18 (72) using a competing-risks model, with relapse and death as competing factors, respectively. Cumulative incidences of grade II–IV acute GVHD and chronic GVHD were estimated developed thrombotic microangiopathic anemia (TMA). accounting for death and relapse as competing events. Acute Immunosuppression was discontinued in 10 patients earlier GVHD and chronic GVHD were graded using NIH consensus than scheduled due to acute kidney injury (AKI) (7), TMA criteria [17]. Venoocclusive disease (VOD) and thrombotic (1), or AKI + TMA (2). No patients developed pneumocystis microangiopathy (TMA) were diagnosed based on criteria pneumonia, cytomegalovirus pneumonitis, or infectious cause defined by the Blood and Marrow Transplant Clinical Trial of death in the absence of GVHD. Substitution with alternate Network [18]. All statistical analyses were performed using R immunosuppression with mycophenolate or prednisone was version 3.3.2. sufficient in these patients to prevent breakthrough acute Patient characteristics are summarized in Table 1.Median GVHD. The cumulative incidence of chronic GVHD was age was 55 (20–72) years. The majority of patients were 32% (Fig. 1b). The 2-year incidences of NRM and relapse transplanted for myeloid malignancies (60%); 72% of patients were 20.3 and 36%, respectively (Fig. 1c). Two-year RFS received reduced intensity conditioning. and OS were 43.3 and 51.3%, respectively (Fig. 1d). The Median follow-up from the day of stem cell infusion (day 7.5 year RFS and OS were 38.5 and 41.1%, respectively. At 0) for surviving patients was 1496 days (607–2719 days). The 7.5 years of follow-up, only 3 of 9 patients were off cumulative incidence of grade II–IV acute GVHD occurring immunosuppression. prior to day 100 was 24%, with no grade III–IV disease Our report is a unique study of solely MMUD transplant (Fig. 1a). Late-onset acute GVHD (defined as acute GVHD recipients [16, 19]. The addition of sirolimus to tacrolimus and occurred beyond day 100 post-transplantation) occurred in an low-dose methotrexate effectively prevented severe acute additional 16% of patients, typically following or shortly GVHD within the first 3–4monthswithalowrateofserious thereafter taper of immunosuppression, and was mostly stages adverse events (i.e., TMA and VOD) and NRM. However, III–IV. Two patients (8%) developed VOD and 3 (12%) tacrolimus-/siroliumus-related toxicities, mostly renal Ann Hematol (2019) 98:237–240 239 Fig. 1 Cumulative incidences of acute GVHD (a), chronic GVHD (b), relapse and non-relapsed mortality (NRM) (c), and overall survival (OS) and relapse-free survival (RFS) (d) insufficiency, prevented the completion of the planned regi- GVHD and NRM [21]. The comparative efficacy of such men in a significant proportion of patients. Nonetheless, early methods with regard to disease control is unknown. breakthrough acute GVHD did not occur after the omission or Acknowledging several limitations, including the relatively substitution of another agent for either tacrolimus or sirolimus. small sample size of this study and the relatively high inci- Unfortunately, the rate of late-onset acute GVHD was sub- dence of regimen modifications due to side effects, the long- stantial, coincident with tapering of sirolimus or tacroliumus. term outcomes presented herein appear similar to reported Long-term immunosuppression has been required in most sur- outcomes of other GVHD prevention methods for patients viving recipients.
Load more

Recommended publications
  • PPE Requirements Hazardous Drug Handling
    This document’s purpose is only to provide general guidance. It is not a definitive interpretation for how to comply with DOSH requirements. Consult the actual NIOSH hazardous drugs list and program regulations in entirety to understand all specific compliance requirements. Minimum PPE Required Minimum PPE Required Universal (Green) - handling and disposed of using normal precautions. PPE Requirements High (Red) - double gloves, gown, eye and face protection in Low (Yellow) - handle at all times with gloves and appropriate engineering Hazardous Drug Handling addition to any necessary controls. engineering controls. Moderate (Orange) -handle at all times with gloves, gown, eye and face protection (with splash potential) and appropirate engineering controls. Tablet Open Capsule Handling only - Contained Crush/Split No alteration Crush/Split Dispensed/Common Drug Name Other Drug Name Additional Information (Formulation) and (NIOSH CATEGORY #) Minimum PPE Minimum PPE Minimum PPE Minimum PPE Required required required required abacavir (susp) (2) ziagen/epzicom/trizivir Low abacavir (tablet) (2) ziagen/epzicom/trizivir Universal Low Moderate acitretin (capsule) (3) soriatane Universal Moderate anastrazole (tablet) (1) arimidex Low Moderate High android (capsule) (3) methyltestosterone Universal Moderate apomorphine (inj sq) (2) apomorphine Moderate arthotec/cytotec (tablet) (3) diclofenac/misoprostol Universal Low Moderate astagraf XL (capsule) (2) tacrolimus Universal do not open avordart (capsule) (3) dutasteride Universal Moderate azathioprine
    [Show full text]
  • Drug-Induced Sexual Dysfunction in Men and Women
    VOLUME 36 : NUMBER 2 : APRIL 2013 ARTICLE Drug-induced sexual dysfunction in men and women Helen M Conaglen whether the clinician is willing to ask about sexual Clinical psychologist and SUMMARY issues and does so in a sensitive way.7,8 Senior research fellow Many medical conditions and their treatments Patients on long-term medications may not be John V Conaglen aware that their sexual problems have developed Endocrinologist and contribute to sexual dysfunction. as a result of their treatment. Conversely some may Associate professor in Commonly implicated drugs include Medicine blame their drugs for sexual problems which are due Sexual Health Research Unit antihypertensives, antidepressants, to relationship difficulties or other stressors. Some Waikato Clinical School antipsychotics and antiandrogens. doctors consider that asking patients if they had Faculty of Medical and Understanding the potential for drug-induced noticed any sexual adverse effects from their drugs Health Sciences University of Auckland sexual problems and their negative impact may ‘suggest’ them to the patient, and possibly result on adherence to treatment will enable the in non-adherence. Patients attributing their sexual clinician to tailor treatments for the patient problems to their drugs are less likely to continue the Key words treatment even when necessary for their health.9 The antidepressants, and his or her partner. consultation should include discussion of the patient’s antihypertensives, Encouraging a discussion with the patient sexual issues so these can be considered in treatment antipsychotics, arousal, about sexual function and providing erectile dysfunction, decisions. hypoactive sexual desire strategies to manage the problem are critical disorder, male impotence, to good clinical care.
    [Show full text]
  • Guideline for Preoperative Medication Management
    Guideline: Preoperative Medication Management Guideline for Preoperative Medication Management Purpose of Guideline: To provide guidance to physicians, advanced practice providers (APPs), pharmacists, and nurses regarding medication management in the preoperative setting. Background: Appropriate perioperative medication management is essential to ensure positive surgical outcomes and prevent medication misadventures.1 Results from a prospective analysis of 1,025 patients admitted to a general surgical unit concluded that patients on at least one medication for a chronic disease are 2.7 times more likely to experience surgical complications compared with those not taking any medications. As the aging population requires more medication use and the availability of various nonprescription medications continues to increase, so does the risk of polypharmacy and the need for perioperative medication guidance.2 There are no well-designed trials to support evidence-based recommendations for perioperative medication management; however, general principles and best practice approaches are available. General considerations for perioperative medication management include a thorough medication history, understanding of the medication pharmacokinetics and potential for withdrawal symptoms, understanding the risks associated with the surgical procedure and the risks of medication discontinuation based on the intended indication. Clinical judgement must be exercised, especially if medication pharmacokinetics are not predictable or there are significant risks associated with inappropriate medication withdrawal (eg, tolerance) or continuation (eg, postsurgical infection).2 Clinical Assessment: Prior to instructing the patient on preoperative medication management, completion of a thorough medication history is recommended – including all information on prescription medications, over-the-counter medications, “as needed” medications, vitamins, supplements, and herbal medications. Allergies should also be verified and documented.
    [Show full text]
  • Corticosteroid Interactions with Cyclosporine, Tacrolimus, Mycophenolate, and Sirolimus: Fact Or Fiction?
    Transplantation Corticosteroid Interactions with Cyclosporine, Tacrolimus, Mycophenolate, and Sirolimus: Fact or Fiction? Stefanie Lam, Nilufar Partovi, Lillian SL Ting, and Mary HH Ensom he discovery and use of 4 classes of Timmunosuppressive agents (ie, cal- OBJECTIVE: To review the current clinical evidence on the effects of corticosteroid cineurin inhibitors, mammalian target of interactions with the immunosuppressive drugs cyclosporine, tacrolimus, myco- rapamycin [mTOR], antimetabolites, phenolate, and sirolimus. corticosteroids) have led to tremendous DATA SOURCES: Articles were retrieved through MEDLINE (1966–February 2008) improvements in short-term outcomes of using the terms corticosteroids, glucocorticoids, immunosuppressants, cyclo- solid organ transplantation. The goal of sporine, tacrolimus, mycophenolate, sirolimus, drug interactions, CYP3A4, P- glycoprotein, and UDP-glucuronosyltransferases. Bibliographies were manually immunosuppression is to prevent rejec- searched for additional relevant articles. tion of the transplanted organ while min- STUDY SELECTION AND DATA EXTRACTION: All English-language studies dealing imizing drug-related toxicity. The cal- with drug interactions between corticosteroids and cyclosporine, tacrolimus, cineurin inhibitors, cyclosporine and mycophenolate, and sirolimus were reviewed. tacrolimus, are potent inhibitors of T cells, DATA SYNTHESIS: Corticosteroids share common metabolic and transporter acting at a point of activation between re- pathways, the cytochrome P450 and P-glycoprotein (P-gp/ABCB1)
    [Show full text]
  • Medical Therapy for Pediatric Vascular Anomalies
    79 Medical Therapy for Pediatric Vascular Anomalies Judith F. Margolin, MD1 Heather Mills Soni, CPNP1 Sheena Pimpalwar, MD2 1 Baylor College of Medicine, Texas Children’sCancerandHematology Address for correspondence Judith F. Margolin, MD, Department of Service, Houston, Texas Pediatrics, Baylor College of Medicine, Texas Children’sCancerand 2 Division of Interventional Radiology, Department of Radiology, TCH, Hematology Service, Suite 1510, Clinical Care Center, 6701 Fannin Baylor College of Medicine, Houston, Texas Street, Houston, Texas 77030 (e-mail: [email protected]). Semin Plast Surg 2014;28:79–86. Abstract Vascular anomalies (VAs) comprise a large variety of individual diagnoses that in different phases of treatment require a diverse number of medical specialists to provide optimal care. Medical therapies include agents usually associated with cancer chemo- therapy, such as vincristine, as well more immunomodulatory types of drugs, such as Keywords glucocorticoids and sirolimus. These immunomodulating drugs are being successfully ► vascular anomalies applied in cases that are typically categorized as vascular tumors, including kaposiform ► chemotherapy hemangioendothelioma (KHE) and tufted angioma (TA), as well as some of the more ► sirolimus invasive types of vascular malformations (i.e., microcystic lymphatic malformations and ► kaposiform blue rubber bleb nevus syndrome (BRBNS). These therapies need to be combined with hemangio- good supportive care, which often involves anticoagulation, antimicrobial prophylaxis, endothelioma
    [Show full text]
  • Diapositiva 1
    4CPS-082 BACKGROUND: • Nephrogenic diabetes insipidus (NDI) results from the inability of the late distal tubules and collecting ducts to respond to vasopressin. • The lack of ability to concentrate urine results in polyuria and polidipsia. • NDI is almost always drug induced; however, there are other causes of it that are acquired, such as electrolyte abnormalities as hypokalemia or hypercalcemia. OBJECTIVE: • To describe a case of nephrogenic diabetes insipidus (NDI) associated with the long-term use and high-dose liposomal amphotericin B. METHODS: • Data were obtained from electronic medical records RESULTS: A 39 years old man diagnosed with diffuse large B-cell non-Hodgkin Lymphoma underwent an allogeneic bone marrow transplant. After a few months, the disease’s progression was detected and immunosuppressive treatment was suspended (February 2014). Rescue treatment was: Gemcitabine and Vinorelbine. In May, the patient was admitted to the hospital with graft-versus-host disease grade III, intestinal form. He was treated with: cyclosporine, micophenolate, sirolimus, methylprednisolone, oral and rectal beclametasone. Additionally, as antimicrobial prophylaxis were meropenem, acyclovir, levofloxacine, cotrimoxazole and caspofungine. In June, serum galactomannan antigen test was positive and invasive pulmonary aspergillosis was diagnosed. Aspergillus fumigatus and Aspergillus flavus were isolated. The patient was started on liposomal amphotericin B 6mg/kg (440 mg) daily during 41 days (accumulated dosage: 18.04g). Voriconazol was rejected because of concomitant treatment with sirolimus. During the treatment, his serum potassium was decreased <1.5mEq/L and it was difficult to maintain >3 mEq/L during the treatment with significant polyuria (urine output was >6litr/day). Nephrogenic diabetes insipidus(NDI) was diagnosed.
    [Show full text]
  • Sirolimus, Everolimus) Symptom Management Oxygen Rehab/Exercise Antidepressants/Anxiolytics Inhalers Lung Transplant Roadmap
    Drug Therapy for LAM Maryl Kreider, MD Director, ILD Program, Penn Lung Center, Philadelphia, PA (Drug) Therapy For LAM Disease Modifying MTOR inhibitors (sirolimus, everolimus) Symptom Management Oxygen Rehab/exercise Antidepressants/Anxiolytics Inhalers Lung transplant Roadmap Sirolimus What is it? Why in LAM? Nuts and Bolts Old therapies Future therapies Sirolimus Rapamycin = Rapamune = Sirolimus First of a class of medications called mTOR inhibitors Discovered in a soil sample on Easter Island – initially used as an antibiotic Now most common use is as a immunosuppressant in patients who have had transplants Also used in heart stents to stop them from getting clogged and as a cancer therapy (kidney cancer and some lymphomas) Sirolimus mTOR is an enzyme that lives in human cells and is part of a long and complex chain of interactions that control cell growth Blocking mTOR should reduce the growth of cells that are rapidly dividing Taveira-DaSilva and Moss. Rev Port Pneumol. Doesn’t kill the cells – 2012;18:142-4 just slows growth Sirolimus Other mTOR inhibitors Everlimus (Affinitor) Temsirolimus SIROLIMUS IN LAM Why sirolimus? Tuberous sclerosis complex is a genetic disorder with know abnormalities of TSC1 and TSC2 genes that lead to abnormal TSC1 and 2 proteins Some patients with TSC develop LAM We know that TSC1 and 2 stimulate the mTOR enzyme So the theory was if you block mTOR perhaps you would effect LAM CAST Trial Cincinnati Angiomyolipoma Sirolimus Trial (CAST) Looked at the effect of taking sirolimus for a year on the size of the AMLs (kidney growths) CAST Bissler et al.
    [Show full text]
  • CVS Specialty® Pharmacy Distribution Drug List Providing One of the Broadest Offerings of Specialty Pharmaceuticals in the Industry
    July 2021 Updated Quarterly CVS Specialty® Pharmacy Distribution Drug List Providing one of the broadest offerings of specialty pharmaceuticals in the industry The CVS Specialty Pharmacy Distribution Drug List is a guide of medications available and distributed through CVS Specialty. Our goal is to help make your life better. With more than 40 years of experience, CVS Specialty provides quality care and service. Our network of pharmacies includes certifications and accreditations from the Joint Commission, Utilization Review Accreditation Commission (URAC), the National Association of Boards of Pharmacy (NABP) and the Accreditation Commission for Health Care (ACHC). These nationally recognized symbols reflect an organization’s commitment to meet highest standards of quality, compliance and safety. This list is updated quarterly. Below brand-name products are in CAPS, and generic products are shown in lowercase italics. Prospective Patients: Ready to get started? Enroll to get your medications from CVS Specialty. Health Care Providers: Visit the CVS Specialty website to download enrollment forms or call 1-800-237-2767 (TTY: 711). Therapy Class Brand Name Generic Name Acromegaly BYNFEZIA PEN octreotide acetate (SANDOSTATIN) SANDOSTATIN SANDOSTATIN LAR SOMATULINE DEPOT SOMAVERT Alcohol/Opioid Dependency PROBUPHINE IMPLANT KIT SUBLOCADE VIVITROL Allergen Immunotherapy ORALAIR PALFORZIA Alpha-1 Antitrypsin Deficiency ARALAST NP GLASSIA ZEMAIRA Amyloidosis ONPATTRO VYNDAMAX VYNDAQEL Anemia ARANESP EPOGEN PROCRIT REBLOZYL RETACRIT Asthma CINQAIR DUPIXENT FASENRA NUCALA XOLAIR Atopic Dermatitis DUPIXENT Botulinum Toxins DYSPORT MYOBLOC XEOMIN Cardiac Disorders ARCALYST dofetilide (TIKOSYN) TIKOSYN Specialty and non-specialty products distributed by CVS Specialty, as well as products covered by a member’s prescription or medical benefit plan, may change from time to time.
    [Show full text]
  • Rapamycin: Drug Repurposing in SARS-Cov-2 Infection
    pharmaceuticals Review Rapamycin: Drug Repurposing in SARS-CoV-2 Infection Jiri Patocka 1,2 , Kamil Kuca 2,3,* , Patrik Oleksak 3 , Eugenie Nepovimova 3, Martin Valis 4, Michal Novotny 4 and Blanka Klimova 4 1 Institute of Radiology, Toxicology and Civil Protection, Faculty of Health and Social Studies, University of South Bohemia Ceske Budejovice, 37005 Ceske Budejovice, Czech Republic; [email protected] 2 Biomedical Research Centre, University Hospital, 50003 Hradec Kralove, Czech Republic 3 Department of Chemistry, Faculty of Science, University of Hradec Kralove, 50003 Hradec Kralove, Czech Republic; [email protected] (P.O.); [email protected] (E.N.) 4 Department of Neurology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, 50003 Hradec Kralove, Czech Republic; [email protected] (M.V.); [email protected] (M.N.); [email protected] (B.K.) * Correspondence: [email protected]; Tel.: +420-603-289-166 Abstract: Since December 2019, SARS-CoV-2 (COVID-19) has been a worldwide pandemic with enormous consequences for human health and the world economy. Remdesivir is the only drug in the world that has been approved for the treating of COVID-19. This drug, as well as vaccination, still has uncertain effectiveness. Drug repurposing could be a promising strategy how to find an appropriate molecule: rapamycin could be one of them. The authors performed a systematic literature review of available studies on the research describing rapamycin in association with COVID-19 infection. Only peer-reviewed English-written articles from the world’s acknowledged databases Web of Science, PubMed, Springer and Scopus were involved.
    [Show full text]
  • CYTOTOXIC and NON-CYTOTOXIC HAZARDOUS MEDICATIONS
    CYTOTOXIC and NON-CYTOTOXIC HAZARDOUS MEDICATIONS1 CYTOTOXIC HAZARDOUS MEDICATIONS NON-CYTOTOXIC HAZARDOUS MEDICATIONS Altretamine IDArubicin Acitretin Iloprost Amsacrine Ifosfamide Aldesleukin Imatinib 3 Arsenic Irinotecan Alitretinoin Interferons Asparaginase Lenalidomide Anastrazole 3 ISOtretinoin azaCITIDine Lomustine Ambrisentan Leflunomide 3 azaTHIOprine 3 Mechlorethamine Bacillus Calmette Guerin 2 Letrozole 3 Bleomycin Melphalan (bladder instillation only) Leuprolide Bortezomib Mercaptopurine Bexarotene Megestrol 3 Busulfan 3 Methotrexate Bicalutamide 3 Methacholine Capecitabine 3 MitoMYcin Bosentan MethylTESTOSTERone CARBOplatin MitoXANtrone Buserelin Mifepristone Carmustine Nelarabine Cetrorelix Misoprostol Chlorambucil Oxaliplatin Choriogonadotropin alfa Mitotane CISplatin PACLitaxel Cidofovir Mycophenolate mofetil Cladribine Pegasparaginase ClomiPHENE Nafarelin Clofarabine PEMEtrexed Colchicine 3 Nilutamide 3 Cyclophosphamide Pentostatin cycloSPORINE Oxandrolone 3 Cytarabine Procarbazine3 Cyproterone Pentamidine (Aerosol only) Dacarbazine Raltitrexed Dienestrol Podofilox DACTINomycin SORAfenib Dinoprostone 3 Podophyllum resin DAUNOrubicin Streptozocin Dutasteride Raloxifene 3 Dexrazoxane SUNItinib Erlotinib 3 Ribavirin DOCEtaxel Temozolomide Everolimus Sirolimus DOXOrubicin Temsirolimus Exemestane 3 Tacrolimus Epirubicin Teniposide Finasteride 3 Tamoxifen 3 Estramustine Thalidomide Fluoxymesterone 3 Testosterone Etoposide Thioguanine Flutamide 3 Tretinoin Floxuridine Thiotepa Foscarnet Trifluridine Flucytosine Topotecan Fulvestrant
    [Show full text]
  • Sirolimus Pharmacokinetics Variability Points to the Relevance of Therapeutic Drug Monitoring in Pediatric Oncology
    pharmaceutics Article Sirolimus Pharmacokinetics Variability Points to the Relevance of Therapeutic Drug Monitoring in Pediatric Oncology Amelia-Naomi Sabo 1,2, Sarah Jannier 3 , Guillaume Becker 2,4, Jean-Marc Lessinger 1, Natacha Entz-Werlé 3,5,* and Véronique Kemmel 1,2,* 1 Laboratoire de Biochimie et Biologie Moléculaire, Hôpitaux Universitaires de Strasbourg, 67200 Strasbourg, France; [email protected] (A.-N.S.); [email protected] (J.-M.L.) 2 Laboratoire de Pharmacologie et Toxicologie Neurocardiovasculaire, Unité de Recherche 7296, Faculté de Médecine de Maïeutique et des Métiers de la Santé, Centre de Recherche en Biomédecine de Strasbourg (CRBS), 67085 Strasbourg, France; [email protected] 3 Unité d’Onco-Hématologie Pédiatrique, Hôpitaux Universitaires de Strasbourg, 67200 Strasbourg, France; [email protected] 4 Service de la Pharmacie, Hôpitaux Universitaires de Strasbourg, 67200 Strasbourg, France 5 Unité Mixte de Recherche (UMR) 7021, Centre National de la Recherche Scientifique (CNRS), Laboratoire de Bioimagerie et Pathologies, Signalisation Tumorale et Cibles Thérapeutiques, Faculté de Pharmacie, Université de Strasbourg, 67401 Illkirch, France * Correspondence: [email protected] (N.E.-W.); [email protected] (V.K.); Tel.: +33-(0)-3-8812-7533 (V.K.) Abstract: Sirolimus is widely used in transplantation, where its therapeutic drug monitoring (TDM) is well established. Evidence of a crucial role for sirolimus in the PI3K/AkT/mTor pathway has Citation: Sabo, A.-N.; Jannier, S.; stimulated interest in its involvement in neoplasia, either as monotherapy or in combination with Becker, G.; Lessinger, J.-M.; other antineoplastic agents. However, in cancer, there is no consensus on sirolimus TDM.
    [Show full text]
  • Cyclophosphamide Improves Engraftment in Patients with SCD and Severe Organ Damage Who Undergo Haploidentical PBSCT
    REGULAR ARTICLE Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT Courtney D. Fitzhugh,1,2 Matthew M. Hsieh,2 Tiffani Taylor,2 Wynona Coles,2 Katherine Roskom,1 Delon Wilson,1 Elizabeth Wright,3 Neal Jeffries,4 Christopher J. Gamper,5 Jonathan Powell,5 Leo Luznik,5 and John F. Tisdale2 1Sickle Cell Branch, National Heart, Lung, and Blood Institute (NHLBI), 2Molecular and Clinical Hematology Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and NHLBI, 3Office of the Clinical Director, NIDDK, and 4Division of Cardiovascular Sciences, Office of Biostatistics Research, NHLBI, National Institutes of Health, Bethesda, MD; and 5Sidney Kimmel Comprehensive Cancer Research Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD Peripheral blood stem cell transplantation (PBSCT) offers a curative option for sickle cell Key Points disease (SCD). Although HLA-matched sibling transplantation is promising, the vast majority • Patients with SCD and of patients lack such a donor. We sought to develop a novel nonmyeloablative HLA- severe organ damage haploidentical PBSCT approach that could safely be used for patients with severe organ can tolerate non- damage. Based on findings in our preclinical model, we developed a phase 1/2 trial myeloablative condi- using alemtuzumab, 400 cGy total body irradiation, and escalating doses of posttransplant tioning with no cyclophosphamide (PT-Cy): 0 mg/kg in cohort 1, 50 mg/kg in cohort 2, and 100 mg/kg in cohort transplant-related b mortality. 3. A total of 21 patients with SCD and 2 with -thalassemia received a transplant.
    [Show full text]